See also faustmanlab.org and pubmed.org faustman dl. Even those well versed in murder know that corporations have no soul and can cause great death and needless suffering.
I hope that Pope Francis will bless and support the work of Ristori.
Novartis's Profit Climbs Ahead of Broad Revamp
Updated July 18, 2014 1:05 a.m. ET
ZURICH—
Novartis AG
NOVN.VX -0.31%
said strong sales at the core drug businesses it will retain
after a $25 billion revamp underpinned 1.6% growth in second-quarter net
profit.
Basel-based Novartis said
revenue from its main products—drugs launched since 2009 or that have
market exclusivity until 2018—rose 18%.
These
treatments, which include multiple-sclerosis pill Gilenya and cancer
drug Afinitor, generated $4.7 billion in sales, or nearly a third of the
company's total revenue in the quarter.
Revenue growth was also robust in China, Russia and other emerging markets, rising 8% when measured in constant currency.
In
contrast, revenue at the company's vaccines business, which it is in
the process of selling, declined 14% in constant currency, to $240
million. Novartis attributed the drop to an unfavorable comparison
created by a large bulk sale a year earlier.
Overall, revenue rose about 2%, to $14.64 billion. Novartis's net profit rose to $2.56 billion.
Novartis's
overall performance narrowly missed analyst expectations but was good
enough for the drug company to stick to its full-year outlook—for group
sales to grow in the low- and mid-single-digit range. The company also
said it expected core operating income, a measure of profitability, to
grow faster than sales, a range of the mid-to-high single digits.
The
results come as Novartis prepares to complete a complex series of
transactions announced earlier this year that will leave the company
focused on pharmaceuticals, generics and eye care. Novartis reckons
these areas are where it has the size and reach to compete as the global
pharmaceutical industry consolidates.
As
part of the reshaping, Novartis is exiting from some businesses,
including vaccines and animal health, which it is selling to competitors
GlaxoSmithKline
GSK.LN +0.61%
PLC and
Eli Lilly
LLY +1.94%
& Co.
In an interview, Chief
Executive
Joe Jimenez
said the transactions remained "on track" and that the company
was filing necessary paperwork with antitrust authorities. The company
also has "a number of teams" working on the process of integrating and
deintegrating the businesses involved in the deals.
"As
you can imagine, there's a very high level of activity," Mr. Jimenez
said. The transactions are expected to be completed in the first half of
2015.
Michael Romer,
an analyst at J. Safra Sarasin, said the results were lackluster
but expressed optimism momentum for the company would pick up in the
second half of the year as the company's growth and cost-savings
initiatives kick in.
Novartis also said
it was appointing
Eric Cornut,
a longtime Novartis employee, to the newly created position of
chief ethics, compliance and policy officer starting on Aug. 1.
Pope Francis 'excommunicates' mafia - The Guardian
Jun 22, 2014 - Pope Francis 'excommunicates' mafia. Pontiff issues strongest attack on organised crime by papacy in two decades and comforts father of boy ...
Neurology. 2014 Jan 7;82(1):41-8. doi: 10.1212/01.wnl.0000438216.93319.ab. Epub 2013 Dec 4.
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS.
Ristori G1, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M.
Abstract
OBJECTIVE:
To evaluate Bacille Calmette-Guérin (BCG) effects after clinically isolated syndromes (CIS).METHODS:
In a double-blind, placebo-controlled trial, participants were randomly assigned to receive BCG or placebo and monitored monthly with brain MRI (6 scans). Both groups then entered a preplanned phase with IM interferon-β-1a for 12 months. From month 18 onward, the patients took the disease-modifying therapies (DMTs) that their neurologist considered indicated in an open-label extension phase lasting up to 60 months.RESULTS:
Of 82 randomized subjects, 73 completed the study (33 vaccinated and 40 placebo). During the initial 6 months, the number of cumulative lesions was significantly lower in vaccinated people. The relative risks were 0.541 (95% confidence interval [CI] 0.308-0.956; p = 0.03) for gadolinium-enhancing lesions (the primary endpoint), 0.364 (95% CI 0.207-0.639; p = 0.001) for new and enlarging T2-hyperintense lesions, and 0.149 (95% CI 0.046-0.416; p = 0.001) for new T1-hypointense lesions. The number of total T1-hypointense lesions was lower in the BCG group at months 6, 12, and 18: mean changes from baseline were -0.09 ± 0.72 vs 0.75 ± 1.81 (p = 0.01), 0.0 ± 0.83 vs 0.88 ± 2.21 (p = 0.08), and -0.21 ± 1.03 vs 1.00 ± 2.49 (p = 0.02). After 60 months, the cumulative probability of clinically definite multiple sclerosis was lower in the BCG + DMT arm (hazard ratio = 0.52, 95% CI 0.27-0.99; p < 0.05), and more vaccinated people remained DMT-free (odds ratio = 0.20, 95% CI 0.04-0.93; p = 0.04).CONCLUSIONS:
Early BCG may benefit CIS and affect its long-term course.CLASSIFICATION OF EVIDENCE:
BCG, as compared to placebo, was associated with significantly reduced development of gadolinium-enhancing lesions in people with CIS for a 6-month period before starting immunomodulating therapy (Class I evidence).Comment in
- BCG vaccine for clinically isolated syndrome and MS: infections and protective immunity. [Neurology. 2014]
- Multiple sclerosis: disease activity is reduced in CIS after BCG vaccination. [Nat Rev Neurol. 2014]
- PMID:
- 24306002
- [PubMed - indexed for MEDLINE]
- PMCID:
- PMC3873620
- [Available on 2015/1/7]
Ristori
G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P,
Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M,
Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti
M.
Neurology. 2014 Jan 7;82(1):41-8. doi: 10.1212/01.wnl.0000438216.93319.ab. Epub 2013 Dec 4.
- PMID:
- 24306002
- [PubMed - indexed for MEDLINE]
J Neurol Sci. 2014 Jun 17. pii: S0022-510X(14)00383-9. doi: 10.1016/j.jns.2014.06.013. [Epub ahead of print]
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Hellmann MA1, Lev N1, Lotan I1, Mosberg-Galili R1, Inbar E2, Luckman J2, Fichman-Horn S3, Yakimov M3, Steiner I4.
Abstract
Finglimod,
a sphingosine 1-phosphate receptor modulator, is the first orally
administered therapy approved for prophylaxis in multiple sclerosis
(MS). Several reports in the last two years suggested that it might be
associated with severe augmentation of disease activity upon initiation
or discontinuation of therapy. We present an MS patient who developed a
giant cavitating brain lesion under fingolimod
and in whom cessation of therapy was associated with a very active
course. Brain biopsy revealed the lesion to be due to an active
demyelinating inflammatory process. With the current wave of
immunosuppressive treatments for MS, there is a need to be vigilant to side effects
and risks not identified in large multicenter trials, collect the data
and set guidelines and precautions for present and future medications.
KEYWORDS:
Fingolimod; Immune-suppression; Multiple sclerosis; Side effects; Therapy; Tumefective- PMID:
- 25001515
- [PubMed - as supplied by publisher]
| Websites |
|---|
-
- ch.linkedin.com/pub/eric-cornut/7/591/616
Background
Experience
Honors & Awards
Chevalier de l'Ordre National du Mérite
République Française
Languages
English
Full professional proficiencyFrench
Native or bilingual proficiencyGerman
Native or bilingual proficiencyItalian
Full professional proficiencyDutch
Full professional proficiency
Education
BCG and Autoimmunity Working Group Publishes First Book
* Reuters is not responsible for the content in this press release.
BCG and Autoimmunity Working Group Publishes First Book
“The Value of BCG and TNF in Autoimmunity” now available from Elsevier
The BCG and Autoimmunity Working Group announced today the availability
of a new book, The
Value of BCG and TNF in Autoimmunity, edited by
Denise
Faustman, MD, PhD, of Massachusetts General Hospital and Harvard Medical
School. Published by Elsevier under the Academic
Press imprint, the book is the first comprehensive overview of
research underway with the bacillus Calmette-Guerin (BCG) vaccine and
tumor necrosis factor (TNF) induction in autoimmune conditions. The book
features proceedings from the First
International Conference on BCG and TNF Signaling in the Treatment and
Prevention of Autoimmune Diseases, which was held in London, UK, in
October 2013. A follow-up conference is being scheduled for the fall of
2015.
Known for almost a century as a tuberculosis vaccine, BCG has shown promise in preclinical studies and in recent human clinical trials as an immune-modifying therapy for long-term diabetes and other autoimmune diseases. The rationale behind the drug’s use in autoimmunity is its ability to make the immune system produce a protein known as TNF in response to perceived danger, such as the introduction of bacteria or viruses, in the body. Autoreactive T cells, which attack the body’s own cells and tissues, appear to be particularly sensitive to the effects of TNF. Hopefully, certain autoimmune diseases can be treated by stimulating TNF to incite apoptosis, or programmed cell death, in autoimmune T cells.
“The goal of this book, the conference and the formation of our working group is to establish an ongoing collaboration among BCG researchers, advocates and funders. We have begun to understand the potential for this safe and affordable vaccine to improve, prevent and possibly reverse autoimmune diseases that, at the present time, are largely incurable. We look forward to the 2015 conference, updated book editions and broader collaborations as more members join the working group,” said Dr. Faustman.
BCG is actively being studied as a treatment for autoimmune diseases such as type 1 diabetes and multiple sclerosis, which do not currently have a cure. The new book summarizes the international scientific research on the possible treatment of autoimmunity with BCG or TNF induction, and provides a rationale for the use of BCG at the forefront of clinical trials in autoimmunity. The Value of BCG and TNF in Autoimmunity is intended for clinical researchers and scientists working in the autoimmunity or immunology fields.
Dr. Faustman is Director of the Immunobiology Laboratory at Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She is currently leading the BCG Human Clinical Trials Program at MGH, which will soon launch a Phase II study to investigate BCG as a treatment to reverse advanced type 1 diabetes.
The book is available at the Elsevier Store and on ScienceDirect, Elsevier’s full-text scientific database offering journal articles and book chapters from more than 2,200 peer-reviewed journals, almost 900 serials and 25,000 book titles.
A private media briefing will be held in New York City on Wednesday, May 7th, from 8:30 to 9:30 a.m. For more information, please contact Russell LaMontagne at Russell@corinthgroup.com
About the BCG and Autoimmunity Working Group
Organized by Dr. Denise Faustman of Massachusetts General Hospital and Harvard Medical School, the BCG and Autoimmunity Working Group was formed to bring together an international group of researchers who are investigating the use of the bacillus Calmette-Guerin (BCG) vaccine and/or tumor necrosis factor (TNF) induction in the context of autoimmune disease prevention and treatment. The First International Conference on BCG and TNF Signaling in the Treatment and Prevention of Autoimmune Diseases, which was the inaugural meeting of this group, was held in London, UK, in October 2013. For more information, please visit: www.facebook.com/BCGautoimmunity.
Media:
For BCG and Autoimmunity Working Group
Russell LaMontagne, 617.464.4641
Russell@corinthgroup.com
No comments:
Post a Comment